EUVIMEDEUVIMED entdecken
Open Access

Cryopreservation of siRNA-Treated Cells Is Feasible

Melanie Sauer, Xavier Segarra-Visent, Leon Breuer, Vasileios Tzirtziganis, Tatyana Ryaykenen, David A Cooper, Dimas Echeverria, Anastasia Kremer, Reka A Haraszti iD

Nucleic Acid Therapeutics · 2025-12 · 35 (6) · 280-285

DOI: 10.1177/21593337251381041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 23.12.2025. Verfasst von Melanie Sauer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Cryopreservation, RNA, Small Interfering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryopreservation is a routine step in the manufacturing process of adoptive cell therapies (ACT), providing critical logistic flexibility. RNA interference (RNAi)-based therapies are increasingly being explored as enhancers or modulators of ACT. However, the impact of cryopreservation on cells treated with RNAi-based therapies has not been investigated before. In this study, we addressed this knowledge gap by examining silencing efficacy in small interfering RNA (siRNA)-treated cells that undergo cryopreservation. Our findings demonstrate that silencing in cryopreserved cells is comparable to that in cells maintained continuously in culture. Moreover, we found that the duration of siRNA exposure plays a significant role in cells that later undergo cryopreservation, with extended exposure improving silencing efficiency. However, this effect diminishes at higher siRNA concentrations. Additionally, we showed that siRNA treatment is feasible at low temperatures (2°C–8°C), and siRNA-treated cells can be cryopreserved for extended periods (at least 1 month) without loss of efficacy. Our work establishes the feasibility of integrating siRNA treatments into current manufacturing processes for ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CryopreservationRNA, Small InterferingHumansRNA InterferenceCell Survival

Stichwörter der Autor:innen

adoptive cell therapycryopreservationoligonucleotidesiRNA

Substanzen

RNA, Small Interfering

Autor:innen und Institutionen

  • Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany.
  • Gene and RNA Therapy Center (GRTC), Faculty of Medicine, University Tuebingen, Tübingen, Germany.
  • RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.

ORCID-Profile: Reka A Haraszti

Förderung

  • NIH HHS

Zitieren

APA

Sauer, M., Segarra-Visent, X., Breuer, L., Tzirtziganis, V., Ryaykenen, T., Cooper, D. A., Echeverria, D., Kremer, A., & Haraszti, R. A. (2025). Cryopreservation of siRNA-Treated Cells Is Feasible. Nucleic Acid Therapeutics, 35(6), 280-285. https://doi.org/10.1177/21593337251381041

Vancouver

Sauer M, Segarra-Visent X, Breuer L, Tzirtziganis V, Ryaykenen T, Cooper DA, et al. Cryopreservation of siRNA-Treated Cells Is Feasible. Nucleic Acid Therapeutics. 2025;35(6):280-285. doi:10.1177/21593337251381041

BibTeX
@article{Sauer2025,
  author = {Sauer, Melanie and Segarra-Visent, Xavier and Breuer, Leon and Tzirtziganis, Vasileios and Ryaykenen, Tatyana and Cooper, David A and Echeverria, Dimas and Kremer, Anastasia and Haraszti, Reka A},
  title = {Cryopreservation of siRNA-Treated Cells Is Feasible},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  volume = {35},
  number = {6},
  pages = {280--285},
  doi = {10.1177/21593337251381041}
}
Kostenlos starten →